全文获取类型
收费全文 | 691篇 |
免费 | 37篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 16篇 |
妇产科学 | 12篇 |
基础医学 | 155篇 |
口腔科学 | 6篇 |
临床医学 | 68篇 |
内科学 | 163篇 |
皮肤病学 | 9篇 |
神经病学 | 120篇 |
特种医学 | 12篇 |
外科学 | 35篇 |
预防医学 | 55篇 |
眼科学 | 7篇 |
药学 | 47篇 |
中国医学 | 1篇 |
肿瘤学 | 24篇 |
出版年
2024年 | 2篇 |
2023年 | 4篇 |
2022年 | 11篇 |
2021年 | 13篇 |
2020年 | 9篇 |
2019年 | 9篇 |
2018年 | 15篇 |
2017年 | 10篇 |
2016年 | 11篇 |
2015年 | 7篇 |
2014年 | 11篇 |
2013年 | 32篇 |
2012年 | 59篇 |
2011年 | 76篇 |
2010年 | 33篇 |
2009年 | 36篇 |
2008年 | 53篇 |
2007年 | 69篇 |
2006年 | 57篇 |
2005年 | 62篇 |
2004年 | 36篇 |
2003年 | 43篇 |
2002年 | 30篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 5篇 |
1998年 | 11篇 |
1997年 | 7篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有731条查询结果,搜索用时 15 毫秒
721.
722.
Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis 总被引:7,自引:0,他引:7
Pierre Wolkenstein Oliver Chosidow Marie-Laure Fléchet Odile Robbiola Muriel Paul Laurence Dume Jean Renuz Jean-Claude Roujeau 《Contact dermatitis》1996,35(4):234-236
Patch testing may help to assess the culpability of a drug in an adverse reaction. Our aim was to study patch testing in severe cutaneous ad verse drug reactions [ADRs] (Stevens-Johnson syndromeitoxic epidermal necrolysis (SJS/TEN). acute genera exanthematous pustulosis (AGEP), and other cutaneous ADRs). 59 patients with cutaneous ADRs were included: 22 had SJS/TEN. 14 AGEP, and 23 other cutaneous ADRs. Patients were patch tested with the suspect drug and with H standard series of drugs. 2 patients among the 22 SJSTEN cases had a relevant positive test. 7 patients among the 14 AGEP cases had a relevant positive test. 6 patients among the 23 other cutaneous ADRs had a relevant positive test. Our results suggest that patch testing has a weak sensitivity in SJS'TEN and is not appropriate in these diseases. Patch testing seems more adapted to other cutaneous ADRs, such as AC it: P. in which the proportion of positive patch tests was significantly higher (P<0.02). Nevertheless, the difference of sensitivity of patch testing in SJS TEN, AGEP or other cutaneous ADRs could be linked not only to the clinical type of eruption, but also lo the different spectrum of culprit drugs in each type of eruption. 相似文献
723.
724.
Lepreux S Doudnikoff E Aubert I Bioulac-Sage P Bloch B Martin-Negrier ML 《Ultrastructural pathology》2008,32(5):178-183
Human telomerase comprises a catalytic protein subunit (hTERT) and an RNA subunit (hTR). Telomerase extends chromosome ends in compensation for the attrition of the telomeres during replication. In this work, the authors explore the expression of hTERT and hTR in neutrophils, respectively by immunochemistry techniques and in situ hybridization. hTERT was strongly expressed in neutrophils cytoplasm. The ultrastructural study showed that the gold particles were not associated with specific organelles but scattered in the cytosol. hTR was not expressed. hTERT is expressed in the cytoplasm of neutrophils, but its roles-eventually extratelomeric effects-remain to be elucidated. 相似文献
725.
Borel P Benkhoucha M Weber MS Zamvil SS Santiago-Raber ML Lalive PH 《International immunology》2008,20(10):1313-1319
Glatiramer acetate (GA, copolymer-1, Copaxone), a therapy approved for treatment of multiple sclerosis (MS), prevents and reverses experimental autoimmune encephalomyelitis, the animal model of MS. In central nervous system autoimmune disease, GA is thought to act through modulation of antigen-presenting cells, such as monocytes, mediating an antigen-independent T(h)2 shift and development of FoxP3+ regulatory T cells. Recent reports indicate that GA may also be effective in models of other autoimmune diseases such as uveoretinitis, inflammatory bowel disease and graft rejection. To date, the potential effect of GA in lupus animal models has not been described. (NZB x BXSB)F1, male mice bearing Y-linked autoimmune acceleration , is a lupus-prone mouse model which is associated with a monocytosis accelerating disease progression. These mice were treated with GA before disease onset until death and both mortality rate and biological parameters were assessed to investigate whether GA may be beneficial in this spontaneous model of systemic lupus erythematosus. GA exerted no beneficial effect on the median survival after up to 7 months of treatment. Humoral and cellular parameters used as markers for lupus progression, such as anti-chromatin, anti-double-stranded DNA and anti-erythrocytes antibodies, hematocrit and monocytosis, were similarly unchanged. Our study demonstrates that GA has no significant effect on the progression of the (NZB x BXSB)F1 lupus-prone animal model. These results reinforce the hypothesis that GA may exert its beneficial effect in some specific autoimmune diseases only. 相似文献
726.
Joanne Ryan Isabelle Carrière Helene Amieva Olivier Rouaud Claudine Berr Karen Ritchie Pierre-Yves Scarabin Marie-Laure Ancelin 《European neuropsychopharmacology》2013,23(12):1763-1768
A plethora of data suggests a role for estrogen in cognitive function and genetic variants in the estrogen receptors ESR1 and ESR2 have been implicated in a range of hormone-sensitive diseases. It remains unknown however, whether ESR polymorphisms are associated with the risk of decline in specific domains of cognitive function. Data came from 3799 non-demented, community-dwelling elderly women recruited in France to the 3C Study. A short cognitive test battery was administered at baseline and 2, 4 and 7 years follow-up to assess global function, verbal fluency, visual memory, psychomotor speed and executive function. Detailed socio-demographic, behavioral, physical and mental health information was also gathered and genotyping of five common ESR1 and ESR2 polymorphisms was also performed. In multivariable-adjusted Cox analysis, ESR1 rs2234693 and rs9340799 were not significantly associated with the risk of decline on any of the cognitive tasks. However, significant associations with ESR2 polymorphisms were identified. The A allele of rs1256049 was associated with an increased risk of substantial decline in visual memory (HR:1.64, 95% CI: 1.23–2.18, p=0.0007), psychomotor speed (HR:1.43, 95% CI: 1.12–1.83, p=0.004), and on the incidence of Mild Cognitive Impairment (HR:1.31, 95% CI: 1.05–1.64, p=0.02). There was also a weaker association between the A allele of rs4986938 and a decreased risk of decline in psychomotor speed. Our large multicentre prospective study provides preliminary evidence that ESR2 genetic variants may be associated with specific cognitive domains and suggests that further examination of the role of this gene in cognitive function is warranted. 相似文献
727.
Ellen E. Fitzsimmons-Craft PhD Agatha A. Laboe BA Claire McGinnis BA Marie-Laure Firebaugh LMSW Jillian Shah BS Michael Wallendorf PhD Corinna Jacobi PhD Anna M. Bardone-Cone PhD Kathleen M. Pike PhD C. Barr Taylor MD Denise E. Wilfley PhD 《The International journal of eating disorders》2023,56(3):654-661
728.
Marie-Laure Girardin Thomas Flamand Ombeline Roignot Marie-Thérèse Abi Warde Véronique Mutschler Paul Voulleminot Max Guillot Vera Dinkelacker Anne De Saint-Martin 《Epilepsia》2023,64(6):e87-e92
New onset refractory status epilepticus (NORSE) is a rare and devastating condition occurring in a previously healthy patient. It is called febrile infection-related epilepsy syndrome (FIRES) when preceded by a febrile infection. It often leads to intensive care treatment, including antiseizure drugs in combination with anesthetic agents, and sometimes ketogenic diet. The mortality rate is high, and severe epileptic and neuropsychiatric sequelae are usually observed. Based on the possible role of neuroinflammation, intravenous immunoglobulin, corticosteroids, and immunomodulatory treatment (anti-IL1, IL6) can be added. We describe here a child and a young adult with FIRES, both treated with tocilizumab. We observed a rapid positive response on the status epilepticus and good tolerance, but different neurological outcomes for our two patients. Further prospective studies may be necessary both to confirm the efficacy and the safety of this promising treatment and to optimize the immunomodulatory strategy in FIRES/NORSE. 相似文献
729.
Meletios A. Dimopoulos Philippe Moreau Bradley Augustson Nelson Castro Tomas Pika Sosana Delimpasi Javier De la Rubia Angelo Maiolino Tony Reiman Joaquin Martinez-Lopez Thomas Martin Joseph Mikhael Kwee Yong Marie-Laure Risse Gaelle Asset Sylvia Marion Roman Hajek 《American journal of hematology》2023,98(1):E15-E19
730.